Lower serum prohepcidin levels associated with lower iron and erythropoietin requirements in hemodialysis patients with chronic hepatitis C

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Caliskan, Yasar ^a   Yelken, Berna ^a   Ozkok, Abdullah ^a   Gorgulu, Numan ^a   Yazici, Halil ^a   Telci, Aysegul ^a   Yildiz, Alaattin ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Ferritin; Hemodialysis; Hepatitis C; Hepcidin; Inflammation; Iron metabolism

Indexed keywords

ANTIANEMIC AGENT; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; FERRITIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROHEPCIDIN; RECOMBINANT ERYTHROPOIETIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; INDEPENDENT VARIABLE; IRON BINDING CAPACITY; IRON BLOOD LEVEL; IRON METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PREDICTION; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; CYTOKINES; ERYTHROPOIETIN; FEMALE; HEPATITIS, CHRONIC; HUMANS; IRON; MALE; MIDDLE AGED; PROTEIN PRECURSORS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 84863441543     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-56     Document Type: Article

References (23)

1. Hepatitis C and renal disease: an update. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH, Am J Kidney Dis 2003 42 631 657 10.1016/S0272-6386(03)00828-X 14520615 (Pubitemid 37187365)
2. Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival. Batty DS, Swanson SJ, Kirk AD, Ko CW, Agodoa LY, Abbott KC, Am J Transplant 2001 1 179 184 10.1034/j.1600-6143.2001.10213.x 12099367 (Pubitemid 33674159)
3. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. Schneeberger PM, Keur I, van Loon AM, et al. J Infect Dis 2000 182 1291 1299 10.1086/315869 11023452
4. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Metwally MA, Zein CO, Zein NN, Am J Gastroenterol 2004 99 2 286 291 10.1111/j.1572-0241.2004.04049.x 15046219 (Pubitemid 38279871)
5. Regulation of iron acquisition and storage: consequences for iron-linked disorders. DeDomenico I, McVey Ward D, Kaplan J, Nat Rev Mol Cell Biol 2008 9 72 81 10.1038/nrm2295 17987043
6. Hepcidin regulates iron efflux by binding to ferroportin and inducing its internalization. Nemeth E, Tuttle MS, Powelson J, et al. Science 2004 306 2090 2093 10.1126/science.1104742 15514116 (Pubitemid 40007660)
7. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Costa E, Swinkels DW, Laarakkers CM, et al. Acta Haematol 2009 122 4 226 229 10.1159/000253590 19887781
8. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Costa E, Pereira BJ, Rocha-Pereira P, et al. Am J Nephrol 2008 28 4 677 683 10.1159/000121478 18354252 (Pubitemid 351832456)
9. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA, Hepatology 2008 48 5 1420 1429 10.1002/hep.22486 18671304
10. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Fujita N, Sugimoto R, Takeo M, et al. Mol Med 2007 13 1-2 97 104 17515961 (Pubitemid 46786838)
11. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Nishina S, Hino K, Korenaga M, et al. Gastroenterology 2008 134 226 238 10.1053/j.gastro.2007.10.011 18166355 (Pubitemid 350309316)
12. Lower erythropoietin and iron supplementation are required in hemodialysis patients with hepatitis C virus infection. Altintepe L, Kurtoglu E, Tonbul Z, Yeksan M, Yildiz A, Turk S, Clin Nephrol 2004 61 5 347 351 15182130 (Pubitemid 38579021)
13. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease [published erratum. National Kidney Foundation, Am J Kidney Dis 2006 48 3 518 Am J Kidney Dis 2006, 47(5 Suppl 3): S1-145
14. Regulatory failure of serum prohepcidin levels in patients with hepatitis C. Nagashima M, Kudo M, Chung H, et al. Hepatol Res 2006 36 288 293 10.1016/j.hepres.2006.08.006 16979376 (Pubitemid 44718431)
15. Reduced serum hepcidin levels in patients with chronic hepatitis C. Girelli D, Pasino M, Goodnough JB, et al. J Hepatol 2009 51 5 845 852 10.1016/j.jhep.2009.06.027 19729219
16. Serum prohepcidin levels in chronic hepatitis C, alcoholic liver disease, and nonalcoholic fatty liver disease. Lee SH, Jeong SH, Park YS, et al. Korean J Hepatol 2010 16 3 288 294 10.3350/kjhep.2010.16.3.288 20924211
17. Hepcidin, a new iron regulatory peptide. Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S, Blood Cells Mol Dis 2002 29 3 327 335 10.1006/bcmd.2002.0573 12547223
18. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Nemeth E, Rivera S, Gabayan V, et al. J Clin Invest 2004 113 1271 1276 15124018 (Pubitemid 39069926)
19. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Nemeth E, Valore EV, Territo M, et al. Blood 2003 101 7 2461 2463 10.1182/blood-2002-10-3235 12433676 (Pubitemid 36857598)
20. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremiathe good, the bad, and the ugly. Stenvinkel P, Ketteler M, Johnson RJ, et al. KidneyInt 2005 67 4 1216 1233 (Pubitemid 40463099)
21. Decreased phorbol myristate acetate-induced release of tumor necrosis factor-alpha and interleukin-1 beta from peripheral blood monocytes of patients chronically infected with hepatitis C virus. Mendoza EC, Paglieroni TG, Zeldis JB, J Infect Dis 1996 174 842 844 10.1093/infdis/174.4.842 8843226 (Pubitemid 26325904)
22. CD30 induction and cytokine profiles in hepatitis C virus core -specific peripheral blood T lymphocytes. Woitas RP, Lechmann M, Jung G, et al. J Immunol 1997 159 1012 1018 9218624 (Pubitemid 127484258)
23. Serum hepcidin in clinical specimens. Dallalio G, Fleury T, Means RT, Br J Haematol 2003 122 996 1000 10.1046/j.1365-2141.2003.04516.x 12956771 (Pubitemid 37174621)